Stifel Maintains Staar Surgical(STAA.US) With Buy Rating, Maintains Target Price $50
Stifel Nicolaus Sticks to Their Buy Rating for Staar Surgical (STAA)
Morgan Stanley Cuts STAAR to Underweight, Cites Growth Expectations
Morgan Stanley Downgrades Staar Surgical to Underweight, Lowers Price Target to $37
Staar Surgical Analyst Ratings
Staar Surgical Analyst Ratings
BTIG Upgrades Staar Surgical to Buy, Announces $46 Price Target
Staar Surgical: A Hold Rating Amidst Conservative Guidance and Modest Growth Prospects
Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $43
Staar Surgical Analyst Ratings
Piper Sandler Maintains Neutral on Staar Surgical, Raises Price Target to $40
Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating
What 7 Analyst Ratings Have To Say About Staar Surgical
Staar Surgical Analyst Ratings
Mizuho Maintains Buy on Staar Surgical, Raises Price Target to $55
Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating
Staar Surgical Hold Rating Maintained Amid Modest Growth and Strategic Caution
Staar Surgical (STAA) Gets a Hold From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Pliant Therapeutics (PLRX) and Crinetics Pharmaceuticals (CRNX)
Staar Surgical Poised for Growth in Refractive Surgery Market, Maintains Buy Rating